Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy

Grants and Contracts Details

StatusActive
Effective start/end date2/4/206/2/23

Funding

  • Merck Sharp & Dohme Corporation: $42,184.00